MRDAC: CT 4003 - An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG(R)-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma (in collaboration with MediGene AG, Martinsried)

CT 4003 - An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG(R)-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in patients with a carcinomatous primary tumor other than hepatocellular (HCC), biliary or bile duct carcinoma.

Ansprechpartner: Dr. Ulrike Fasol
Tel: 0049-761-270-7411
Email: ulrike.fasol@uniklinik-freiburg.de

Projektbeginn: 01.11.2007
Projektende: 31.10.2008

Hennig J.
Stellvertretung: Dr. Martin Büchert
Albert-Ludwigs-Universität Freiburg
Department für Radiologische Diagnostik und Therapie
Klinik für Radiologie
Hugstetterstrasse 55
79106 Freiburg

Telefon: +49-761-270-38050/38060
Fax: +49-761-270-38380

• Drittmittel, Firma

MediGene Studie, MRDAC